What Are GLP-1 Agonists and How Do They Work?

As a primary care physician with a focus on longevity, I've seen a surge of interest in a class of medications called GLP-1 agonists. The vast majority of my patients are either interested in or now trying one form of a GLP-1 or another. You've probably heard buzz about medications like Ozempic, Wegovy, Mounjaro, or Zepbound. These drugs have been making headlines for their effectiveness in treating type 2 diabetes and obesity. But what exactly are these medications, and how do they work their magic? Let's dive into the world of GLP-1 agonists and unravel their mechanisms.

Understanding GLP-1 Agonists

GLP-1 agonists, short for Glucagon-Like Peptide-1 receptor agonists, are a group of medications that mimic a natural hormone in your body called GLP-1. An "agonist" is a substance that binds to a receptor and activates it, producing an effect similar to that of the natural substance. In this case, GLP-1 agonists activate the GLP-1 receptors in your body, playing a crucial role in regulating blood sugar levels and appetite. Some well-known GLP-1 agonists include:

1. Semaglutide (brand names: Ozempic, Wegovy, Rybelsus)
2. Liraglutide (Victoza, Saxenda)
3. Dulaglutide (Trulicity)
4. Tirzepatide (Mounjaro, Zepbound) - a dual GIP and GLP-1 receptor agonist

Think of GLP-1 as a superhero in your digestive system. When you eat, your body releases this hormone to help manage your blood sugar levels and signal fullness to your brain. GLP-1 agonists are like artificial superheroes that step in to do the same job, but they stick around longer than the natural hormone.

The Science Behind GLP-1 Agonists

To understand how GLP-1 agonists work, we need to look at their effects on various parts of the body:

1. Pancreas: Boosting Insulin and Suppressing GlucagonGLP-1 agonists stimulate the pancreas to produce more insulin when blood sugar levels are high. Insulin is the hormone responsible for moving glucose from the bloodstream into cells where it can be used for energy.At the same time, these medications suppress the release of glucagon, another pancreatic hormone that typically raises blood sugar. This dual action helps keep blood glucose levels in check.
2. Stomach and Intestines: Slowing DigestionOne of the key effects of GLP-1 agonists is their ability to slow gastric emptying. This means food stays in your stomach longer, leading to a more gradual rise in blood sugar after meals and a prolonged feeling of fullness.
3. Brain: Reducing Appetite and Food IntakeGLP-1 agonists act on the hypothalamus, a region of the brain that regulates hunger and satiety. By mimicking the natural GLP-1 hormone, these medications send signals to the brain that you're not hungry, which can help reduce overall food intake.
4. Cardiovascular System: Potential Heart BenefitsSome studies suggest that GLP-1 agonists may have protective effects on the heart and blood vessels, potentially reducing the risk of cardiovascular events in people with type 2 diabetes.

A Kitchen Analogy to Understand GLP-1 Agonists

Let's use an analogy to understand this better. Imagine your body as a busy restaurant kitchen. Insulin is the head chef who takes sugar from the "pantry" (your bloodstream) and stores it properly in the "refrigerator" (your cells). In type 2 diabetes, the head chef (insulin) isn't working efficiently and works harder and yells louder (you get higher insulin levels or insulin-resistance).

GLP-1 agonists are like skilled kitchen assistants who:

1. Help the head chef (insulin) work better
2. Slow down how quickly new "ingredients" (food) are coming into the kitchen
3. Turn down the heat on the stove that's producing too much sugar (by suppressing glucagon)
4. Tell the "customers" (your brain) that they're full and don't need to order more food

Who Might Use GLP-1 Agonists?

Doctors often prescribe these medications for people with type 2 diabetes who need help controlling their blood sugar. More recently, some GLP-1 agonists have also been approved for weight loss in people with obesity, even if they don't have diabetes.

For example, Sarah, a 45-year-old teacher with type 2 diabetes, struggled to keep her blood sugar in check despite diet changes and other medications. Her doctor prescribed a GLP-1 agonist, and within a few months, her blood sugar levels improved significantly. As a bonus, she also lost some weight, which further helped her diabetes management.

Different Types and Administration

GLP-1 agonists come in various forms:

1. Injectable medications: Most GLP-1 agonists are given as subcutaneous injections. Some are taken daily (like Victoza and Saxenda), while others are weekly injections (like Ozempic, Wegovy, Mounjaro, and Zepbound).
2. Oral medication: Semaglutide is also available as an oral tablet (Rybelsus), making it the first oral GLP-1 agonist on the market.

The choice between daily and weekly injections often depends on patient preference and lifestyle. Daily injections allow for more flexible dosing but require more frequent administration. Weekly injections are more convenient for many patients but may have a higher incidence of gastrointestinal side effects after each dose. For most patients, in my experience, the weekly administration works better for convenience and weight management.

The choice between these options depends on factors like patient preference, potential side effects, and insurance coverage.

Potential Side Effects and Considerations

While GLP-1 agonists can be very effective, they're not without potential side effects. Common side effects include:

1. Nausea and vomiting (usually temporary)
2. Diarrhea or constipation
3. Headache
4. Injection site reactions

More serious but rare side effects can include pancreatitis or thyroid tumors. It's crucial to discuss these risks with your healthcare provider.

If you experience severe abdominal pain that doesn't go away, vomiting that won't stop, or signs of an allergic reaction like difficulty breathing or swelling of the face, lips, tongue, or throat, seek immediate medical attention.

‍

Lifestyle Modifications

While GLP-1 agonists can be powerful tools for managing diabetes and weight, they work best when combined with healthy lifestyle choices. This includes:

1. Following a balanced, nutritious diet
2. Engaging in regular physical activity
3. Getting adequate sleep
4. Managing stress
5. Monitoring blood sugar levels as recommended by your healthcare provider

The Future of GLP-1 Agonists

Research into GLP-1 agonists is ongoing, with scientists exploring their potential benefits beyond diabetes and weight management. Some areas of interest include:

1. Neurodegenerative diseases like Alzheimer's
2. Non-alcoholic fatty liver disease (NAFLD)
3. Polycystic ovary syndrome (PCOS)

While these applications are still in the research phase, they highlight the exciting potential of this class of medications.

Cost and Insurance Coverage

It's important to note that GLP-1 agonists can be expensive, with some costing over $1,000 per month without insurance. Coverage varies widely between insurance plans, and some may require prior authorization or step therapy. Patients should check with their insurance provider and explore patient assistance programs offered by pharmaceutical companies. There are also great coupon programs by websites like GoodRx and SingleCare, to name a few examples.

The Controversy

The widespread use of GLP-1 agonists for weight loss in non-diabetic individuals has sparked some controversy. While these medications can lead to significant weight loss, there are concerns about long-term safety, the potential for misuse, and the societal implications of medicating obesity. It's a complex issue that requires ongoing research and ethical consideration.

Long-Term Effects and Ongoing Research

While GLP-1 agonists have shown promising results in the short to medium term, research on their long-term effects is still ongoing. Some studies have followed patients for up to 5 years, showing sustained benefits in terms of blood sugar control and weight management. However, as with any relatively new class of medications, the full picture of long-term effects is still emerging.

Current areas of research include:

1. Cardiovascular outcomes: Long-term studies are investigating whether the heart-protective effects observed in shorter trials persist over extended periods.
2. Impact on bone health: Some research suggests a potential effect on bone density, particularly in postmenopausal women, warranting further investigation.
3. Effects on kidney function: While early data suggests potential kidney-protective effects, long-term impacts are still being studied.
4. Sustainability of weight loss: Researchers are exploring how long the weight loss effects last and whether there are rebound effects after discontinuation.
5. Potential neuroprotective effects: Early studies hint at possible benefits for brain health, but more research is needed to confirm these findings.

It's important to note that while we have substantial evidence for the safety and efficacy of these medications in the short to medium term (especially in the diabetic population which has used GLP-1 agonists for longer), long-term data is still accumulating. As with any medication, the decision to use GLP-1 agonists should involve a careful consideration of the known benefits and risks, as well as ongoing monitoring by your healthcare provider.

Conclusion

GLP-1 agonists represent a significant advance in the treatment of type 2 diabetes and obesity or overweight. In my practice, we even consider the potential benefits for overall longevity. By mimicking the body's natural GLP-1 hormone, these medications offer a multi-faceted approach to managing blood sugar and weight.

Remember, everyone's body is different, and what works for one person might not work for another. GLP-1 agonists work best when combined with healthy eating habits and regular exercise.

Key takeaways:

1. GLP-1 agonists mimic a natural hormone to help control blood sugar and reduce appetite.
2. They can be effective for both diabetes management and weight loss.
3. Side effects are generally mild but can be serious in rare cases.
4. These medications work best when combined with healthy lifestyle choices.
5. Cost and insurance coverage can be significant factors to consider.

If you think you might benefit from a GLP-1 agonist, I encourage you to discuss this option with your healthcare provider. They can help you weigh the potential benefits and risks based on your individual health profile and needs.

As our understanding of GLP-1 agonists grows, so does their potential to improve health outcomes for millions of people worldwide. Whether you're familiar with names like Ozempic and Zepbound or just learning about these medications, understanding how they work is the first step in making informed decisions about your health.

References:

1. American Diabetes Association. "Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021." Diabetes Care, 2021.
2. Nauck, M.A., et al. "Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus" Journal of Clinical Investigation, 1993.
3. Buse, J.B., et al. "2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)." Diabetes Care, 2020.
4. Drucker, D.J. "Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1." Cell Metabolism, 2018.
5. Kristensen, S.L., et al. "Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials." Lancet Diabetes & Endocrinology, 2020.
6. Blundell, J., et al. "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity." Diabetes, Obesity and Metabolism, 2017.
7. Rosenstock, J., et al. "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial" Lancet, 2021.
8. Wilding, J.P.H., et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021.

‍

Until next time - Cheers to your health!

Hillary Lin, MD